ES2921020T3 - Compuestos de indol sustituidos con [1,2,4]triazolo[4,3-a]piridinilo - Google Patents
Compuestos de indol sustituidos con [1,2,4]triazolo[4,3-a]piridinilo Download PDFInfo
- Publication number
- ES2921020T3 ES2921020T3 ES18759464T ES18759464T ES2921020T3 ES 2921020 T3 ES2921020 T3 ES 2921020T3 ES 18759464 T ES18759464 T ES 18759464T ES 18759464 T ES18759464 T ES 18759464T ES 2921020 T3 ES2921020 T3 ES 2921020T3
- Authority
- ES
- Spain
- Prior art keywords
- triazolo
- indol
- isopropyl
- piperidin
- pyridine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 [1,2,4]triazolo[4,3-a]pyridinyl-substituted indole compounds Chemical class 0.000 title claims description 122
- 150000001875 compounds Chemical class 0.000 claims abstract description 139
- 150000003839 salts Chemical class 0.000 claims abstract description 36
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 25
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 96
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 50
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 48
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 39
- 125000000217 alkyl group Chemical group 0.000 claims description 39
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 25
- 239000012453 solvate Substances 0.000 claims description 22
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 18
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 18
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims description 17
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 17
- 125000004966 cyanoalkyl group Chemical group 0.000 claims description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 14
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 13
- 201000006417 multiple sclerosis Diseases 0.000 claims description 13
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 13
- 239000003937 drug carrier Substances 0.000 claims description 12
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 12
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 11
- 229910052731 fluorine Inorganic materials 0.000 claims description 10
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 10
- 125000001425 triazolyl group Chemical group 0.000 claims description 10
- 229910052801 chlorine Inorganic materials 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 9
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 9
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 9
- NSOKIUUDFLTYEO-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CC(C)NC(C)C1)C1=CN2C=NN=C2C(C)=C1C Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CC(C)NC(C)C1)C1=CN2C=NN=C2C(C)=C1C NSOKIUUDFLTYEO-UHFFFAOYSA-N 0.000 claims description 8
- 125000003566 oxetanyl group Chemical group 0.000 claims description 8
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 7
- TWNLBKKKAZNPNZ-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC(=O)N(C)C)CC1)C1=CN2C=NN=C2C(C)=C1 Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC(=O)N(C)C)CC1)C1=CN2C=NN=C2C(C)=C1 TWNLBKKKAZNPNZ-UHFFFAOYSA-N 0.000 claims description 7
- ACHRXWKRUCNDOG-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCNCC1)C1=CN2C=NN=C2C=C1 Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCNCC1)C1=CN2C=NN=C2C=C1 ACHRXWKRUCNDOG-UHFFFAOYSA-N 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 7
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 6
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims description 6
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims description 6
- 125000002883 imidazolyl group Chemical group 0.000 claims description 6
- 125000000335 thiazolyl group Chemical group 0.000 claims description 6
- KZKRRZFCAYOXQE-UHFFFAOYSA-N 1$l^{2}-azinane Chemical group C1CC[N]CC1 KZKRRZFCAYOXQE-UHFFFAOYSA-N 0.000 claims description 5
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 5
- CZSRXHJVZUBEGW-UHFFFAOYSA-N 1,2-thiazolidine Chemical compound C1CNSC1 CZSRXHJVZUBEGW-UHFFFAOYSA-N 0.000 claims description 4
- ONRRZBDBUOQGOV-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CC(C)N(CC(=O)N(C)C)C(C)C1)C1=CN2C=NN=C2C(C)=C1C Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CC(C)N(CC(=O)N(C)C)C(C)C1)C1=CN2C=NN=C2C(C)=C1C ONRRZBDBUOQGOV-UHFFFAOYSA-N 0.000 claims description 4
- YKPHJMWPEUBSDI-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC(=O)N(C)C)CC1)C1=C(C)N2C=NN=C2C(C)=C1 Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC(=O)N(C)C)CC1)C1=C(C)N2C=NN=C2C(C)=C1 YKPHJMWPEUBSDI-UHFFFAOYSA-N 0.000 claims description 4
- OTVZNORNOUQHHQ-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC(C)(C)O)CC1)C1=CN2C=NN=C2C(C)=C1 Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC(C)(C)O)CC1)C1=CN2C=NN=C2C(C)=C1 OTVZNORNOUQHHQ-UHFFFAOYSA-N 0.000 claims description 4
- HFTLJQBXNLWAQY-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC1)C(=O)CN(C)C)C1=C(C)N2C=NN=C2C=C1 Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC1)C(=O)CN(C)C)C1=C(C)N2C=NN=C2C=C1 HFTLJQBXNLWAQY-UHFFFAOYSA-N 0.000 claims description 4
- BFGLRTRUWKKCJX-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC1)C(=O)CN(C)C)C1=CN2C=NN=C2C=C1C Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC1)C(=O)CN(C)C)C1=CN2C=NN=C2C=C1C BFGLRTRUWKKCJX-UHFFFAOYSA-N 0.000 claims description 4
- KAAHPGVDDHQJQJ-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC1)C1CC(C)(C)OC(C)(C)C1)C1=CN2C=NN=C2C(C)=C1C Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC1)C1CC(C)(C)OC(C)(C)C1)C1=CN2C=NN=C2C(C)=C1C KAAHPGVDDHQJQJ-UHFFFAOYSA-N 0.000 claims description 4
- CKDTVGFXTCQQDC-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC1)C1CC(C)OC(C)C1)C1=CN2C=NN=C2C(C)=C1C Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC1)C1CC(C)OC(C)C1)C1=CN2C=NN=C2C(C)=C1C CKDTVGFXTCQQDC-UHFFFAOYSA-N 0.000 claims description 4
- IDNFJKYDSYQBTO-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC1)C1CCOC(C)(C)C1)C1=CN2C=NN=C2C(C)=C1C Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC1)C1CCOC(C)(C)C1)C1=CN2C=NN=C2C(C)=C1C IDNFJKYDSYQBTO-UHFFFAOYSA-N 0.000 claims description 4
- SEAWOLFJIAOAAL-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC1)C1CCOCC1)C1=CN2C=NN=C2C(C)=C1 Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC1)C1CCOCC1)C1=CN2C=NN=C2C(C)=C1 SEAWOLFJIAOAAL-UHFFFAOYSA-N 0.000 claims description 4
- UMDDNOWXOKHNEE-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC1)C1CCOCC1)C1=CN2C=NN=C2C=C1C Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC1)C1CCOCC1)C1=CN2C=NN=C2C=C1C UMDDNOWXOKHNEE-UHFFFAOYSA-N 0.000 claims description 4
- PNHIAACRYZELBG-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC1)C1COC1)C1=CN2C(C)=NN=C2C=C1 Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC1)C1COC1)C1=CN2C(C)=NN=C2C=C1 PNHIAACRYZELBG-UHFFFAOYSA-N 0.000 claims description 4
- RYGMUGAZQNTHEA-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC1)C1COC1)C1=CN2C=NN=C2C(C)=C1C Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC1)C1COC1)C1=CN2C=NN=C2C(C)=C1C RYGMUGAZQNTHEA-UHFFFAOYSA-N 0.000 claims description 4
- JUBRWWVPEHKMFK-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC1)C1COC1)C1=CN2C=NN=C2C=C1C Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC1)C1COC1)C1=CN2C=NN=C2C=C1C JUBRWWVPEHKMFK-UHFFFAOYSA-N 0.000 claims description 4
- KZDKZMRGAQBNRU-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC2=NN(C)C=C2)CC1)C1=CN2C(C)=NN=C2C(C)=C1 Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC2=NN(C)C=C2)CC1)C1=CN2C(C)=NN=C2C(C)=C1 KZDKZMRGAQBNRU-UHFFFAOYSA-N 0.000 claims description 4
- RMRUWPSAFBRPRN-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC2=NN(C)C=N2)CC1)C1=CN2C=NN=C2C(C)=C1 Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC2=NN(C)C=N2)CC1)C1=CN2C=NN=C2C(C)=C1 RMRUWPSAFBRPRN-UHFFFAOYSA-N 0.000 claims description 4
- GACLDTDTSOOQSX-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC2=NN(C)C=N2)CC1)C1=CN2C=NN=C2C=C1 Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC2=NN(C)C=N2)CC1)C1=CN2C=NN=C2C=C1 GACLDTDTSOOQSX-UHFFFAOYSA-N 0.000 claims description 4
- OJWJJKTVSNNRAY-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CCCC(F)(F)F)CC1)C1=C(C)N2C=NN=C2C(C)=C1 Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CCCC(F)(F)F)CC1)C1=C(C)N2C=NN=C2C(C)=C1 OJWJJKTVSNNRAY-UHFFFAOYSA-N 0.000 claims description 4
- ZITXFVDRBGVGQI-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CCCC(F)(F)F)CC1)C1=CN2C=NN=C2C(C)=C1 Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CCCC(F)(F)F)CC1)C1=CN2C=NN=C2C(C)=C1 ZITXFVDRBGVGQI-UHFFFAOYSA-N 0.000 claims description 4
- LWDYHGBVUSTVQV-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CCCC(F)(F)F)CC1)C1=CN2C=NN=C2C(C)=C1C Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CCCC(F)(F)F)CC1)C1=CN2C=NN=C2C(C)=C1C LWDYHGBVUSTVQV-UHFFFAOYSA-N 0.000 claims description 4
- PLXGXFDXOHKEGE-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CCS(C)(=O)=O)CC1)C1=CN2C=NN=C2C(C)=C1 Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CCS(C)(=O)=O)CC1)C1=CN2C=NN=C2C(C)=C1 PLXGXFDXOHKEGE-UHFFFAOYSA-N 0.000 claims description 4
- VTIGVNFUUJKAJY-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCNCC1)C1=CN2C(C)=NN=C2C=C1 Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCNCC1)C1=CN2C(C)=NN=C2C=C1 VTIGVNFUUJKAJY-UHFFFAOYSA-N 0.000 claims description 4
- WJSLBOLBWXTTDA-UHFFFAOYSA-N COC1=CC(=CN2C=NN=C12)C1=C(C(C)C)C2=CC(=CC=C2N1)C1CCN(CC1)C1CCOC1 Chemical compound COC1=CC(=CN2C=NN=C12)C1=C(C(C)C)C2=CC(=CC=C2N1)C1CCN(CC1)C1CCOC1 WJSLBOLBWXTTDA-UHFFFAOYSA-N 0.000 claims description 4
- MLAAUSMJWOSBOR-UHFFFAOYSA-N COC1=CC(=CN2C=NN=C12)C1=C(C(C)C)C2=CC(=CC=C2N1)C1CCN(CC1)C1COC1 Chemical compound COC1=CC(=CN2C=NN=C12)C1=C(C(C)C)C2=CC(=CC=C2N1)C1CCN(CC1)C1COC1 MLAAUSMJWOSBOR-UHFFFAOYSA-N 0.000 claims description 4
- MYFXTUCVWXBLOU-UHFFFAOYSA-N COC1=CC(=CN2C=NN=C12)C1=C(C(C)C)C2=CC(=CC=C2N1)C1CCN(CC2(C)COC2)CC1 Chemical compound COC1=CC(=CN2C=NN=C12)C1=C(C(C)C)C2=CC(=CC=C2N1)C1CCN(CC2(C)COC2)CC1 MYFXTUCVWXBLOU-UHFFFAOYSA-N 0.000 claims description 4
- MHZFFYBPSPZDAL-UHFFFAOYSA-N COC1=CC(=CN2C=NN=C12)C1=C(C(C)C)C2=CC(=CC=C2N1)C1CCNCC1 Chemical compound COC1=CC(=CN2C=NN=C12)C1=C(C(C)C)C2=CC(=CC=C2N1)C1CCNCC1 MHZFFYBPSPZDAL-UHFFFAOYSA-N 0.000 claims description 4
- UEOUHKIVVNRWPL-UHFFFAOYSA-N COC1=NC=C(CN2CCC(CC2)C2=CC=C3NC(=C(C(C)C)C3=C2)C2=CN3C=NN=C3C(C)=C2C)C=N1 Chemical compound COC1=NC=C(CN2CCC(CC2)C2=CC=C3NC(=C(C(C)C)C3=C2)C2=CN3C=NN=C3C(C)=C2C)C=N1 UEOUHKIVVNRWPL-UHFFFAOYSA-N 0.000 claims description 4
- SKXYTQIWDVBAHO-UHFFFAOYSA-N COCCN1CCC(CC1)C1=CC=C2NC(=C(C(C)C)C2=C1)C1=CN2C=NN=C2C(C)=C1 Chemical compound COCCN1CCC(CC1)C1=CC=C2NC(=C(C(C)C)C2=C1)C1=CN2C=NN=C2C(C)=C1 SKXYTQIWDVBAHO-UHFFFAOYSA-N 0.000 claims description 4
- XCAIHLXEHHIJGQ-UHFFFAOYSA-N N=1N=CN2C=1C=CC(=C2)C=1NC2=CC=C(C=C2C=1C(C)C)C1CCN(CC1)C(CN(C)C)=O Chemical compound N=1N=CN2C=1C=CC(=C2)C=1NC2=CC=C(C=C2C=1C(C)C)C1CCN(CC1)C(CN(C)C)=O XCAIHLXEHHIJGQ-UHFFFAOYSA-N 0.000 claims description 4
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims description 4
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 4
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 4
- 125000002757 morpholinyl group Chemical group 0.000 claims description 4
- 125000002971 oxazolyl group Chemical group 0.000 claims description 4
- 125000004193 piperazinyl group Chemical group 0.000 claims description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 4
- GTZSFVHJMJKFLH-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC1)C1CCOC1)C1=CN2C=NN=C2C(C)=C1C Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC1)C1CCOC1)C1=CN2C=NN=C2C(C)=C1C GTZSFVHJMJKFLH-UHFFFAOYSA-N 0.000 claims description 3
- ORIZTQXCWYYLEV-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC2=CN=C(C)N=C2)CC1)C1=CN2C=NN=C2C(C)=C1C Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC2=CN=C(C)N=C2)CC1)C1=CN2C=NN=C2C(C)=C1C ORIZTQXCWYYLEV-UHFFFAOYSA-N 0.000 claims description 3
- HMOJRGCWGBBQIX-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC2=NN(C)C=N2)CC1)C1=CN2C=NN=C2C(C)=C1C Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC2=NN(C)C=N2)CC1)C1=CN2C=NN=C2C(C)=C1C HMOJRGCWGBBQIX-UHFFFAOYSA-N 0.000 claims description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 208000037976 chronic inflammation Diseases 0.000 claims description 3
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 3
- 235000019256 formaldehyde Nutrition 0.000 claims description 3
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 3
- VMWJCFLUSKZZDX-UHFFFAOYSA-N n,n-dimethylmethanamine Chemical compound [CH2]N(C)C VMWJCFLUSKZZDX-UHFFFAOYSA-N 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims description 2
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 2
- OSOYHEWYWGPZIB-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CC(C)N(C2COC2)C(C)C1)C1=CN2C=NN=C2C(C)=C1C Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CC(C)N(C2COC2)C(C)C1)C1=CN2C=NN=C2C(C)=C1C OSOYHEWYWGPZIB-UHFFFAOYSA-N 0.000 claims description 2
- AAEFWGVPMZODDE-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CC(C)N(CC2(C)COC2)C(C)C1)C1=CN2C=NN=C2C(C)=C1C Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CC(C)N(CC2(C)COC2)C(C)C1)C1=CN2C=NN=C2C(C)=C1C AAEFWGVPMZODDE-UHFFFAOYSA-N 0.000 claims description 2
- WQJWYUJKPSXMKL-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CC(C)N(CCS(C)(=O)=O)C(C)C1)C1=CN2C=NN=C2C(C)=C1C Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CC(C)N(CCS(C)(=O)=O)C(C)C1)C1=CN2C=NN=C2C(C)=C1C WQJWYUJKPSXMKL-UHFFFAOYSA-N 0.000 claims description 2
- XJLGCAOMEMUIJM-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCNCC1)C1=C(C)N2C=NN=C2C(C)=C1 Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCNCC1)C1=C(C)N2C=NN=C2C(C)=C1 XJLGCAOMEMUIJM-UHFFFAOYSA-N 0.000 claims description 2
- JPHGXVDBQRIUCT-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCNCC1)C1=CN2C(C)=NN=C2C(C)=C1 Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCNCC1)C1=CN2C(C)=NN=C2C(C)=C1 JPHGXVDBQRIUCT-UHFFFAOYSA-N 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 125000002393 azetidinyl group Chemical group 0.000 claims description 2
- 125000004799 bromophenyl group Chemical group 0.000 claims description 2
- 125000004965 chloroalkyl group Chemical group 0.000 claims description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 claims description 2
- 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 125000006393 methylpyrimidinyl group Chemical group 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- UYMFYVQMSQRNAI-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC(=O)N(C)C)CC1)C1=C(C)N2C=NN=C2C=C1 Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC(=O)N(C)C)CC1)C1=C(C)N2C=NN=C2C=C1 UYMFYVQMSQRNAI-UHFFFAOYSA-N 0.000 claims 2
- OEFYYVPAJDQGQV-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC(=O)N(C)C)CC1)C1=CN2C=NN=C2C(Cl)=C1C Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC(=O)N(C)C)CC1)C1=CN2C=NN=C2C(Cl)=C1C OEFYYVPAJDQGQV-UHFFFAOYSA-N 0.000 claims 2
- VUEUJCAZHQEKGH-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC(=O)N(C)C)CC1)C1=CN2C=NN=C2C=C1 Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC(=O)N(C)C)CC1)C1=CN2C=NN=C2C=C1 VUEUJCAZHQEKGH-UHFFFAOYSA-N 0.000 claims 2
- UPKXCLCBGHBFFL-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC1)C1CCOCC1)C1=C(C)N2C=NN=C2C=C1 Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC1)C1CCOCC1)C1=C(C)N2C=NN=C2C=C1 UPKXCLCBGHBFFL-UHFFFAOYSA-N 0.000 claims 2
- VZRRVXZAVBBDBF-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC2=NN(C)C=N2)CC1)C1=C(C)N2C=NN=C2C(C)=C1 Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC2=NN(C)C=N2)CC1)C1=C(C)N2C=NN=C2C(C)=C1 VZRRVXZAVBBDBF-UHFFFAOYSA-N 0.000 claims 2
- PQTCIRPCRMQLFA-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CCN2CCCC2=O)CC1)C1=CN2C=NN=C2C(C)=C1C Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CCN2CCCC2=O)CC1)C1=CN2C=NN=C2C(C)=C1C PQTCIRPCRMQLFA-UHFFFAOYSA-N 0.000 claims 2
- SCIZYADMTAAOPA-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CCO)CC1)C1=CN2C=NN=C2C(C)=C1 Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CCO)CC1)C1=CN2C=NN=C2C(C)=C1 SCIZYADMTAAOPA-UHFFFAOYSA-N 0.000 claims 2
- AIDKWRUMHXTKMG-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CCS(C)(=O)=O)CC1)C1=CN2C=NN=C2C(Cl)=C1C Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CCS(C)(=O)=O)CC1)C1=CN2C=NN=C2C(Cl)=C1C AIDKWRUMHXTKMG-UHFFFAOYSA-N 0.000 claims 2
- OFEGAOHKJNAIDS-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCNCC1)C1=CN2C=NN=C2C=C1C Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCNCC1)C1=CN2C=NN=C2C=C1C OFEGAOHKJNAIDS-UHFFFAOYSA-N 0.000 claims 2
- UOBNIOSGLBDYIP-UHFFFAOYSA-N CC(C)c1c([nH]c2ccc(cc12)C1CCN(Cc2ncn(C)n2)CC1)-c1ccc2nncn2c1C Chemical compound CC(C)c1c([nH]c2ccc(cc12)C1CCN(Cc2ncn(C)n2)CC1)-c1ccc2nncn2c1C UOBNIOSGLBDYIP-UHFFFAOYSA-N 0.000 claims 2
- JVAOHMRBAWIPIR-UHFFFAOYSA-N CNC(=O)CN1CCC(CC1)C1=CC=C2NC(=C(C(C)C)C2=C1)C1=CN2C=NN=C2C=C1 Chemical compound CNC(=O)CN1CCC(CC1)C1=CC=C2NC(=C(C(C)C)C2=C1)C1=CN2C=NN=C2C=C1 JVAOHMRBAWIPIR-UHFFFAOYSA-N 0.000 claims 2
- ABQWIYWSBGQEDN-UHFFFAOYSA-N CNC(=O)CN1CCC(CC1)C1=CC=C2NC(=C(C(C)C)C2=C1)C1=CN2C=NN=C2C=C1C Chemical compound CNC(=O)CN1CCC(CC1)C1=CC=C2NC(=C(C(C)C)C2=C1)C1=CN2C=NN=C2C=C1C ABQWIYWSBGQEDN-UHFFFAOYSA-N 0.000 claims 2
- UCICSISLJFTNEL-UHFFFAOYSA-N COC1=CC(=CN2C=NN=C12)C1=C(C(C)C)C2=CC(=CC=C2N1)C1CCN(CCCC(F)(F)F)CC1 Chemical compound COC1=CC(=CN2C=NN=C12)C1=C(C(C)C)C2=CC(=CC=C2N1)C1CCN(CCCC(F)(F)F)CC1 UCICSISLJFTNEL-UHFFFAOYSA-N 0.000 claims 2
- WGUPHZMRYIWQGM-UHFFFAOYSA-N COC1=CC(C2=C(C(C)C)C3=CC(=CC=C3N2)C2CCN(CC(C)(C)O)CC2)=C(C)N2C=NN=C12 Chemical compound COC1=CC(C2=C(C(C)C)C3=CC(=CC=C3N2)C2CCN(CC(C)(C)O)CC2)=C(C)N2C=NN=C12 WGUPHZMRYIWQGM-UHFFFAOYSA-N 0.000 claims 2
- AYSYSOQSKKDJJY-UHFFFAOYSA-N [1,2,4]triazolo[4,3-a]pyridine Chemical compound C1=CC=CN2C=NN=C21 AYSYSOQSKKDJJY-UHFFFAOYSA-N 0.000 claims 2
- WTGHXWCNCLNGJG-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCNCC1)C1=CN2C=NN=C2C(C)=C1C Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCNCC1)C1=CN2C=NN=C2C(C)=C1C WTGHXWCNCLNGJG-UHFFFAOYSA-N 0.000 claims 1
- BZBOIEVNLPQMMJ-UHFFFAOYSA-N COC1=CC(=CN2C=NN=C12)C1=C(C(C)C)C2=CC(=CC=C2N1)C1CCN(C)CC1 Chemical compound COC1=CC(=CN2C=NN=C12)C1=C(C(C)C)C2=CC(=CC=C2N1)C1CCN(C)CC1 BZBOIEVNLPQMMJ-UHFFFAOYSA-N 0.000 claims 1
- VVCBKJXBOXZRPB-UHFFFAOYSA-N COC1=CC(=CN2C=NN=C12)C1=C(C(C)C)C2=CC(=CC=C2N1)C1CCN(CC1)C(C)C Chemical compound COC1=CC(=CN2C=NN=C12)C1=C(C(C)C)C2=CC(=CC=C2N1)C1CCN(CC1)C(C)C VVCBKJXBOXZRPB-UHFFFAOYSA-N 0.000 claims 1
- QYJGBFQMHQZMBZ-UHFFFAOYSA-N COCC1=NN=C2C=CC(=CN12)C1=C(C(C)C)C2=CC(=CC=C2N1)C1CCNCC1 Chemical compound COCC1=NN=C2C=CC(=CN12)C1=C(C(C)C)C2=CC(=CC=C2N1)C1CCNCC1 QYJGBFQMHQZMBZ-UHFFFAOYSA-N 0.000 claims 1
- 125000001539 acetonyl group Chemical group [H]C([H])([H])C(=O)C([H])([H])* 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 44
- 239000003112 inhibitor Substances 0.000 abstract description 10
- 208000027866 inflammatory disease Diseases 0.000 abstract description 8
- 229910052757 nitrogen Inorganic materials 0.000 abstract description 6
- 230000011664 signaling Effects 0.000 abstract description 6
- 230000002757 inflammatory effect Effects 0.000 abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 57
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene chloride Substances ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 55
- 239000000203 mixture Substances 0.000 description 41
- 239000011541 reaction mixture Substances 0.000 description 41
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 37
- 230000014759 maintenance of location Effects 0.000 description 33
- 239000000243 solution Substances 0.000 description 33
- 238000006243 chemical reaction Methods 0.000 description 29
- 235000002639 sodium chloride Nutrition 0.000 description 29
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 28
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 27
- 238000000524 positive electrospray ionisation mass spectrometry Methods 0.000 description 27
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 23
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 22
- 239000000463 material Substances 0.000 description 20
- 102100033110 Toll-like receptor 8 Human genes 0.000 description 19
- 238000005160 1H NMR spectroscopy Methods 0.000 description 18
- 239000012634 fragment Substances 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- 201000010099 disease Diseases 0.000 description 17
- 239000007787 solid Substances 0.000 description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 15
- 239000005695 Ammonium acetate Substances 0.000 description 15
- 235000019257 ammonium acetate Nutrition 0.000 description 15
- 229940043376 ammonium acetate Drugs 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 15
- 239000000725 suspension Substances 0.000 description 14
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 102000002689 Toll-like receptor Human genes 0.000 description 12
- 108020000411 Toll-like receptor Proteins 0.000 description 12
- 239000013058 crude material Substances 0.000 description 12
- 230000007170 pathology Effects 0.000 description 12
- 239000000460 chlorine Substances 0.000 description 11
- 238000010898 silica gel chromatography Methods 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 241000124008 Mammalia Species 0.000 description 10
- 125000004093 cyano group Chemical group *C#N 0.000 description 10
- 235000019439 ethyl acetate Nutrition 0.000 description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000002671 adjuvant Substances 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 239000003995 emulsifying agent Substances 0.000 description 9
- 239000010410 layer Substances 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000003755 preservative agent Substances 0.000 description 8
- 229910052938 sodium sulfate Inorganic materials 0.000 description 8
- 235000011152 sodium sulphate Nutrition 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical class CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 238000001023 centrifugal evaporation Methods 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 150000004665 fatty acids Chemical class 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 108010060752 Toll-Like Receptor 8 Proteins 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 235000013355 food flavoring agent Nutrition 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 239000000080 wetting agent Substances 0.000 description 6
- VZFNWVRVBIKRQZ-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC1)C1COC1)C1=CN2C=NN=C2C(C)=C1 Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC1)C1COC1)C1=CN2C=NN=C2C(C)=C1 VZFNWVRVBIKRQZ-UHFFFAOYSA-N 0.000 description 5
- SHLLVQMYIUKQAD-UHFFFAOYSA-N CC(C)c1c([nH]c2ccc(cc12)C1CC2CCC(C1)N2)-c1cn2cnnc2c(C)c1C Chemical compound CC(C)c1c([nH]c2ccc(cc12)C1CC2CCC(C1)N2)-c1cn2cnnc2c(C)c1C SHLLVQMYIUKQAD-UHFFFAOYSA-N 0.000 description 5
- 206010009900 Colitis ulcerative Diseases 0.000 description 5
- 229920000858 Cyclodextrin Polymers 0.000 description 5
- 108010060825 Toll-Like Receptor 7 Proteins 0.000 description 5
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 5
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 239000007900 aqueous suspension Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000007859 condensation product Substances 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 4
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 4
- NQPFOBVMTOYBRY-UHFFFAOYSA-N C(C)(C)C1=C(NC2=CC=C(C=C12)C1CCNCC1)C=1C=C(C=2N(C=1)C=NN=2)C Chemical compound C(C)(C)C1=C(NC2=CC=C(C=C12)C1CCNCC1)C=1C=C(C=2N(C=1)C=NN=2)C NQPFOBVMTOYBRY-UHFFFAOYSA-N 0.000 description 4
- KPEXORKWTHOFKI-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(Cl)C=C12)C1=CN2C=NN=C2C(C)=C1C Chemical compound CC(C)C1=C(NC2=CC=C(Cl)C=C12)C1=CN2C=NN=C2C(C)=C1C KPEXORKWTHOFKI-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 208000011231 Crohn disease Diseases 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- 201000005569 Gout Diseases 0.000 description 4
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 4
- 208000034578 Multiple myelomas Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 235000019483 Peanut oil Nutrition 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- 206010063837 Reperfusion injury Diseases 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 230000001363 autoimmune Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000012455 biphasic mixture Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 239000000312 peanut oil Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000003828 vacuum filtration Methods 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- FBNRLQRIMLEPOY-UHFFFAOYSA-N 5-bromo-3-propan-2-yl-1h-indole Chemical compound C1=C(Br)C=C2C(C(C)C)=CNC2=C1 FBNRLQRIMLEPOY-UHFFFAOYSA-N 0.000 description 3
- 244000215068 Acacia senegal Species 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 201000006474 Brain Ischemia Diseases 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000009329 Graft vs Host Disease Diseases 0.000 description 3
- 229920000084 Gum arabic Polymers 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 3
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010040070 Septic Shock Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 235000010489 acacia gum Nutrition 0.000 description 3
- 239000000205 acacia gum Substances 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000002491 angiogenic effect Effects 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 208000024908 graft versus host disease Diseases 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 206010025135 lupus erythematosus Diseases 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000004530 micro-emulsion Substances 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 239000000346 nonvolatile oil Substances 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000000123 paper Substances 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- YRHLNCNBWPTVPJ-UHFFFAOYSA-N tert-butyl 4-(2-bromo-3-propan-2-yl-1H-indol-5-yl)piperidine-1-carboxylate Chemical compound BrC=1NC2=CC=C(C=C2C=1C(C)C)C1CCN(CC1)C(=O)OC(C)(C)C YRHLNCNBWPTVPJ-UHFFFAOYSA-N 0.000 description 3
- PWSQLDOOMMRPHP-UHFFFAOYSA-N tert-butyl 4-(3-propan-2-yl-1H-indol-5-yl)-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound C(C)(C)C1=CNC2=CC=C(C=C12)C1=CCN(CC1)C(=O)OC(C)(C)C PWSQLDOOMMRPHP-UHFFFAOYSA-N 0.000 description 3
- BWLYCXBLUREBEX-UHFFFAOYSA-N tert-butyl 4-(3-propan-2-yl-1H-indol-5-yl)piperidine-1-carboxylate Chemical compound C(C)(C)C1=CNC2=CC=C(C=C12)C1CCN(CC1)C(=O)OC(C)(C)C BWLYCXBLUREBEX-UHFFFAOYSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 3
- IHCYKIQCCAIZGI-UHFFFAOYSA-N (5-bromo-3-methylpyridin-2-yl)hydrazine Chemical compound CC1=CC(Br)=CN=C1NN IHCYKIQCCAIZGI-UHFFFAOYSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- GELKGHVAFRCJNA-UHFFFAOYSA-N 2,2-Dimethyloxirane Chemical compound CC1(C)CO1 GELKGHVAFRCJNA-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- VXWVFZFZYXOBTA-UHFFFAOYSA-N 5-bromo-1h-indole Chemical class BrC1=CC=C2NC=CC2=C1 VXWVFZFZYXOBTA-UHFFFAOYSA-N 0.000 description 2
- JLCVSFDCHKCISN-UHFFFAOYSA-N 5-bromo-2-fluoro-3-methylpyridine Chemical compound CC1=CC(Br)=CN=C1F JLCVSFDCHKCISN-UHFFFAOYSA-N 0.000 description 2
- UEQPRYKZXIMKKO-UHFFFAOYSA-N 5-chloro-3-propan-2-yl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole Chemical compound CC(C)C1=C(NC2=CC=C(Cl)C=C12)B1OC(C)(C)C(C)(C)O1 UEQPRYKZXIMKKO-UHFFFAOYSA-N 0.000 description 2
- ZGSFQUYONIPIJE-UHFFFAOYSA-N 6-bromo-3,8-dimethyl-[1,2,4]triazolo[4,3-a]pyridine Chemical compound CC1=CC(Br)=CN2C(C)=NN=C21 ZGSFQUYONIPIJE-UHFFFAOYSA-N 0.000 description 2
- RCWAVMSCPPWENC-UHFFFAOYSA-N 6-bromo-3-(methoxymethyl)-[1,2,4]triazolo[4,3-a]pyridine Chemical compound C1=CC(Br)=CN2C(COC)=NN=C21 RCWAVMSCPPWENC-UHFFFAOYSA-N 0.000 description 2
- SQJJGTRYJKBHNJ-UHFFFAOYSA-N 6-bromo-3-methyl-[1,2,4]triazolo[4,3-a]pyridine Chemical compound C1=CC(Br)=CN2C(C)=NN=C21 SQJJGTRYJKBHNJ-UHFFFAOYSA-N 0.000 description 2
- NSPWKKCAECFRFU-UHFFFAOYSA-N 6-bromo-8-methyl-[1,2,4]triazolo[4,3-a]pyridine Chemical compound CC1=CC(Br)=CN2C=NN=C12 NSPWKKCAECFRFU-UHFFFAOYSA-N 0.000 description 2
- PFKZKSHKBBUZKU-UHFFFAOYSA-N 6-bromo-[1,2,4]triazolo[4,3-a]pyridine Chemical compound C1=C(Br)C=CC2=NN=CN21 PFKZKSHKBBUZKU-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 208000004429 Bacillary Dysentery Diseases 0.000 description 2
- 208000023328 Basedow disease Diseases 0.000 description 2
- 208000020084 Bone disease Diseases 0.000 description 2
- UWKSRPNQPOMOBW-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(C)CC1)C1=CN2C=NN=C2C(C)=C1C Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(C)CC1)C1=CN2C=NN=C2C(C)=C1C UWKSRPNQPOMOBW-UHFFFAOYSA-N 0.000 description 2
- KYZAGRYRELKCBN-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC(=O)N(C)C)CC1)C1=CN2C(C)=NN=C2C(C)=C1 Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC(=O)N(C)C)CC1)C1=CN2C(C)=NN=C2C(C)=C1 KYZAGRYRELKCBN-UHFFFAOYSA-N 0.000 description 2
- GMBBLCURUSJVFM-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC1)C1CCOCC1)C1=C(C)N2C=NN=C2C(C)=C1 Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC1)C1CCOCC1)C1=C(C)N2C=NN=C2C(C)=C1 GMBBLCURUSJVFM-UHFFFAOYSA-N 0.000 description 2
- QLRWUJATEKAHQK-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC1)C1CCOCC1)C1=CN2C(C)=NN=C2C(C)=C1 Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC1)C1CCOCC1)C1=CN2C(C)=NN=C2C(C)=C1 QLRWUJATEKAHQK-UHFFFAOYSA-N 0.000 description 2
- OGXCGQHKENRDDR-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC1)C1CCOCC1)C1=CN2C=NN=C2C(C)=C1C Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC1)C1CCOCC1)C1=CN2C=NN=C2C(C)=C1C OGXCGQHKENRDDR-UHFFFAOYSA-N 0.000 description 2
- XCTVOXUHFIQGNF-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC1)C1CCOCC1)C1=CN2C=NN=C2C(Cl)=C1C Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC1)C1CCOCC1)C1=CN2C=NN=C2C(Cl)=C1C XCTVOXUHFIQGNF-UHFFFAOYSA-N 0.000 description 2
- QEMMYIOXABXNMZ-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC1)C1COC1)C1=CN2C=NN=C2C(Cl)=C1C Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC1)C1COC1)C1=CN2C=NN=C2C(Cl)=C1C QEMMYIOXABXNMZ-UHFFFAOYSA-N 0.000 description 2
- AJLCTDLZAWDKPL-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC1)C1COC1)C1=CN2C=NN=C2C=C1 Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC1)C1COC1)C1=CN2C=NN=C2C=C1 AJLCTDLZAWDKPL-UHFFFAOYSA-N 0.000 description 2
- HFFNFWLJMPYKAA-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC2(C)COC2)CC1)C1=CN2C=NN=C2C(C)=C1 Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC2(C)COC2)CC1)C1=CN2C=NN=C2C(C)=C1 HFFNFWLJMPYKAA-UHFFFAOYSA-N 0.000 description 2
- PJETYJOYEWZUHO-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC2=CN(C)N=N2)CC1)C1=CN2C=NN=C2C(C)=C1C Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC2=CN(C)N=N2)CC1)C1=CN2C=NN=C2C(C)=C1C PJETYJOYEWZUHO-UHFFFAOYSA-N 0.000 description 2
- CCDUCWWZAMLBMD-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC2=CN(C)N=N2)CC1)C1=CN2C=NN=C2C(Cl)=C1C Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC2=CN(C)N=N2)CC1)C1=CN2C=NN=C2C(Cl)=C1C CCDUCWWZAMLBMD-UHFFFAOYSA-N 0.000 description 2
- QNLYABBAJXTCQQ-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC2=NN(C)C=C2)CC1)C1=CN2C=NN=C2C(C)=C1 Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC2=NN(C)C=C2)CC1)C1=CN2C=NN=C2C(C)=C1 QNLYABBAJXTCQQ-UHFFFAOYSA-N 0.000 description 2
- FTLTXWUDJBGZOU-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CCS(C)(=O)=O)CC1)C1=CN2C=NN=C2C(C)=C1C Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CCS(C)(=O)=O)CC1)C1=CN2C=NN=C2C(C)=C1C FTLTXWUDJBGZOU-UHFFFAOYSA-N 0.000 description 2
- OKBDTWCSAQOTAH-UHFFFAOYSA-N CC(C)C1=C(NC2=CC=C(C=C12)C1CCNCC1)C1=CN2C=NN=C2C(Cl)=C1C Chemical compound CC(C)C1=C(NC2=CC=C(C=C12)C1CCNCC1)C1=CN2C=NN=C2C(Cl)=C1C OKBDTWCSAQOTAH-UHFFFAOYSA-N 0.000 description 2
- LCHZVLIYPVYMSF-UHFFFAOYSA-N CC(C)N1CCC(CC1)C1=CC=C2NC(=C(C(C)C)C2=C1)C1=CN2C=NN=C2C(C)=C1C Chemical compound CC(C)N1CCC(CC1)C1=CC=C2NC(=C(C(C)C)C2=C1)C1=CN2C=NN=C2C(C)=C1C LCHZVLIYPVYMSF-UHFFFAOYSA-N 0.000 description 2
- MJEDKWQBYOJLLO-UHFFFAOYSA-N CC1=C(C)C(Br)=CN2C=NN=C12 Chemical compound CC1=C(C)C(Br)=CN2C=NN=C12 MJEDKWQBYOJLLO-UHFFFAOYSA-N 0.000 description 2
- ZNZLJWHVEWLTIS-UHFFFAOYSA-N COC1=CC(=CN2C=NN=C12)C1=C(C(C)C)C2=CC(=CC=C2N1)C1CCN(CC(=O)N(C)C)CC1 Chemical compound COC1=CC(=CN2C=NN=C12)C1=C(C(C)C)C2=CC(=CC=C2N1)C1CCN(CC(=O)N(C)C)CC1 ZNZLJWHVEWLTIS-UHFFFAOYSA-N 0.000 description 2
- LVAAZNJPJFWBGU-UHFFFAOYSA-N COC1=CC(=CN2C=NN=C12)C1=C(C(C)C)C2=CC(=CC=C2N1)C1CCN(CC1)C1CCC(F)(F)CC1 Chemical compound COC1=CC(=CN2C=NN=C12)C1=C(C(C)C)C2=CC(=CC=C2N1)C1CCN(CC1)C1CCC(F)(F)CC1 LVAAZNJPJFWBGU-UHFFFAOYSA-N 0.000 description 2
- XQMABMZKZUMLMK-UHFFFAOYSA-N COC1=CC(=CN2C=NN=C12)C1=C(C(C)C)C2=CC(=CC=C2N1)C1CCN(CC1)C1CCOCC1 Chemical compound COC1=CC(=CN2C=NN=C12)C1=C(C(C)C)C2=CC(=CC=C2N1)C1CCN(CC1)C1CCOCC1 XQMABMZKZUMLMK-UHFFFAOYSA-N 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010018634 Gouty Arthritis Diseases 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 2
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 2
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 201000011152 Pemphigus Diseases 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 2
- 102000003708 Protein arginine N-methyltransferase Human genes 0.000 description 2
- 108020000912 Protein arginine N-methyltransferase Proteins 0.000 description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 206010040550 Shigella infections Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 2
- 102100023118 Transcription factor JunD Human genes 0.000 description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 125000004103 aminoalkyl group Chemical group 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 208000019664 bone resorption disease Diseases 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 208000001969 capillary hemangioma Diseases 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000011111 cardboard Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 208000001763 cytomegalovirus retinitis Diseases 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 208000021039 metastatic melanoma Diseases 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 201000001976 pemphigus vulgaris Diseases 0.000 description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000012041 precatalyst Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 201000005113 shigellosis Diseases 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000020408 systemic-onset juvenile idiopathic arthritis Diseases 0.000 description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- QYQLEYTXFMOLEI-UHFFFAOYSA-N (5-bromopyridin-2-yl)hydrazine Chemical compound NNC1=CC=C(Br)C=N1 QYQLEYTXFMOLEI-UHFFFAOYSA-N 0.000 description 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- HDPNBNXLBDFELL-UHFFFAOYSA-N 1,1,1-trimethoxyethane Chemical compound COC(C)(OC)OC HDPNBNXLBDFELL-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- FHJATBIERQTCTN-UHFFFAOYSA-N 1-[4-amino-2-(ethylaminomethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol Chemical compound C1=CC=CC2=C(N(C(CNCC)=N3)CC(C)(C)O)C3=C(N)N=C21 FHJATBIERQTCTN-UHFFFAOYSA-N 0.000 description 1
- MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- XBPPLECAZBTMMK-UHFFFAOYSA-N 2-chloro-n,n-dimethylacetamide Chemical compound CN(C)C(=O)CCl XBPPLECAZBTMMK-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- GUYGQQWIKZLHTP-UHFFFAOYSA-N 3-bromo-6-fluoro-2-methylpyridine Chemical compound CC1=NC(F)=CC=C1Br GUYGQQWIKZLHTP-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- ROADCYAOHVSOLQ-UHFFFAOYSA-N 3-oxetanone Chemical compound O=C1COC1 ROADCYAOHVSOLQ-UHFFFAOYSA-N 0.000 description 1
- LZPWAYBEOJRFAX-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2$l^{2}-dioxaborolane Chemical compound CC1(C)O[B]OC1(C)C LZPWAYBEOJRFAX-UHFFFAOYSA-N 0.000 description 1
- WWJXARCCHPSXNV-UHFFFAOYSA-N 4-(2-bromo-3-propan-2-yl-1H-indol-5-yl)piperidine-1-carboxylic acid Chemical compound CC(C)C1=C(NC2=C1C=C(C=C2)C3CCN(CC3)C(=O)O)Br WWJXARCCHPSXNV-UHFFFAOYSA-N 0.000 description 1
- KWAGWMGOGGVRHV-UHFFFAOYSA-N 5-bromo-2-fluoro-3-methoxypyridine Chemical compound COC1=CC(Br)=CN=C1F KWAGWMGOGGVRHV-UHFFFAOYSA-N 0.000 description 1
- PFODFMZCBQUYNG-UHFFFAOYSA-N 5-bromo-2-fluoro-4-methylpyridine Chemical compound CC1=CC(F)=NC=C1Br PFODFMZCBQUYNG-UHFFFAOYSA-N 0.000 description 1
- MYUQKYGWKHTRPG-UHFFFAOYSA-N 5-bromo-2-fluoropyridine Chemical compound FC1=CC=C(Br)C=N1 MYUQKYGWKHTRPG-UHFFFAOYSA-N 0.000 description 1
- YAVKJNIMFGZBSY-UHFFFAOYSA-N 5-bromo-3,4-dimethylpyridin-2-amine Chemical compound CC1=C(C)C(N)=NC=C1Br YAVKJNIMFGZBSY-UHFFFAOYSA-N 0.000 description 1
- FSZYOBZOVULXIL-UHFFFAOYSA-N 5-bromo-3,6-dimethylpyridin-2-amine Chemical compound CC1=CC(Br)=C(C)N=C1N FSZYOBZOVULXIL-UHFFFAOYSA-N 0.000 description 1
- DNQBPTJDPUCOOZ-UHFFFAOYSA-N 5-bromo-3-chloro-4-methylpyridin-2-amine Chemical compound BrC=1C(=C(C(=NC=1)N)Cl)C DNQBPTJDPUCOOZ-UHFFFAOYSA-N 0.000 description 1
- JDNCMHOKWINDKI-UHFFFAOYSA-N 5-bromo-4-methylpyridin-2-amine Chemical compound CC1=CC(N)=NC=C1Br JDNCMHOKWINDKI-UHFFFAOYSA-N 0.000 description 1
- MYTGFBZJLDLWQG-UHFFFAOYSA-N 5-chloro-1h-indole Chemical compound ClC1=CC=C2NC=CC2=C1 MYTGFBZJLDLWQG-UHFFFAOYSA-N 0.000 description 1
- AOODTQMDCVJOCB-UHFFFAOYSA-N 5-chloro-3-propan-2-yl-1h-indole Chemical compound C1=C(Cl)C=C2C(C(C)C)=CNC2=C1 AOODTQMDCVJOCB-UHFFFAOYSA-N 0.000 description 1
- ZXVNXGBBBLDGKP-UHFFFAOYSA-N 6-bromo-5-methyl-[1,2,4]triazolo[4,3-a]pyridine Chemical compound Cc1c(Br)ccc2nncn12 ZXVNXGBBBLDGKP-UHFFFAOYSA-N 0.000 description 1
- UBGJFOTUWXQQDK-UHFFFAOYSA-N 6-bromo-7-methyl-[1,2,4]triazolo[4,3-a]pyridine Chemical compound C1=C(Br)C(C)=CC2=NN=CN21 UBGJFOTUWXQQDK-UHFFFAOYSA-N 0.000 description 1
- BRAPQLHVJFCEAD-UHFFFAOYSA-N 6-bromo-8-methoxy-[1,2,4]triazolo[4,3-a]pyridine Chemical compound COc1cc(Br)cn2cnnc12 BRAPQLHVJFCEAD-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010055128 Autoimmune neutropenia Diseases 0.000 description 1
- 208000011594 Autoinflammatory disease Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 241000713704 Bovine immunodeficiency virus Species 0.000 description 1
- YRJDAEUCOORLNH-UHFFFAOYSA-N BrC=1C(=C(C(=NC=1)Cl)C)C Chemical compound BrC=1C(=C(C(=NC=1)Cl)C)C YRJDAEUCOORLNH-UHFFFAOYSA-N 0.000 description 1
- BJADNZRATTWSHN-UHFFFAOYSA-N BrC=1NC2=CC=C(C=C2C=1C(C)C)Cl Chemical compound BrC=1NC2=CC=C(C=C2C=1C(C)C)Cl BJADNZRATTWSHN-UHFFFAOYSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- FMESRRSSSJJDIV-FRIKZZABSA-N CC(C)c1c([nH]c2ccc(cc12)C1C[C@@H]2CC[C@H](C1)N2C1COC1)-c1cn2cnnc2c(C)c1C Chemical compound CC(C)c1c([nH]c2ccc(cc12)C1C[C@@H]2CC[C@H](C1)N2C1COC1)-c1cn2cnnc2c(C)c1C FMESRRSSSJJDIV-FRIKZZABSA-N 0.000 description 1
- LRWOKPJHWTWXLW-NOTZXAQLSA-N CC(C)c1c([nH]c2ccc(cc12)C1C[C@@H]2CC[C@H](C1)N2CC(=O)N(C)C)-c1cn2cnnc2c(C)c1C Chemical compound CC(C)c1c([nH]c2ccc(cc12)C1C[C@@H]2CC[C@H](C1)N2CC(=O)N(C)C)-c1cn2cnnc2c(C)c1C LRWOKPJHWTWXLW-NOTZXAQLSA-N 0.000 description 1
- PFBSRJWXOGYILQ-CWAQXLGLSA-N CC(C)c1c([nH]c2ccc(cc12)C1C[C@@H]2CC[C@H](C1)N2CC1(C)COC1)-c1cn2cnnc2c(C)c1C Chemical compound CC(C)c1c([nH]c2ccc(cc12)C1C[C@@H]2CC[C@H](C1)N2CC1(C)COC1)-c1cn2cnnc2c(C)c1C PFBSRJWXOGYILQ-CWAQXLGLSA-N 0.000 description 1
- JFQHJGTWGGABBD-UHFFFAOYSA-N CC1=C(Cl)C2=NN=CN2C=C1Br Chemical compound CC1=C(Cl)C2=NN=CN2C=C1Br JFQHJGTWGGABBD-UHFFFAOYSA-N 0.000 description 1
- FYULERUXGDAONR-UHFFFAOYSA-N CC1=CC(Br)=C(C)N2C=NN=C12 Chemical compound CC1=CC(Br)=C(C)N2C=NN=C12 FYULERUXGDAONR-UHFFFAOYSA-N 0.000 description 1
- AFAVJYLMWDPBKN-UHFFFAOYSA-N CC1N(C(O)=O)C(C)CC(B2OC(C)(C)C(C)(C)O2)=C1 Chemical compound CC1N(C(O)=O)C(C)CC(B2OC(C)(C)C(C)(C)O2)=C1 AFAVJYLMWDPBKN-UHFFFAOYSA-N 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- 206010063094 Cerebral malaria Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000003606 Congenital Rubella Syndrome Diseases 0.000 description 1
- 101000983970 Conus catus Alpha-conotoxin CIB Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 241000713730 Equine infectious anemia virus Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000713800 Feline immunodeficiency virus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 108091069196 IL-1 family Proteins 0.000 description 1
- 102000039996 IL-1 family Human genes 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101000574441 Mus musculus Alkaline phosphatase, germ cell type Proteins 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- VEPVRLDGTCCPAS-UHFFFAOYSA-N N'-(5-bromopyridin-2-yl)-2-methoxyacetohydrazide Chemical compound BrC=1C=CC(NC=1)=NNC(COC)=O VEPVRLDGTCCPAS-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 208000005074 Retroviridae Infections Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010043781 Thyroiditis chronic Diseases 0.000 description 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 206010048873 Traumatic arthritis Diseases 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
- 229960004748 abacavir Drugs 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 201000005000 autoimmune gastritis Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- WXNOJTUTEXAZLD-UHFFFAOYSA-L benzonitrile;dichloropalladium Chemical compound Cl[Pd]Cl.N#CC1=CC=CC=C1.N#CC1=CC=CC=C1 WXNOJTUTEXAZLD-UHFFFAOYSA-L 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 238000006795 borylation reaction Methods 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229930194791 calphostin Natural products 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- GCUVBACNBHGZRS-UHFFFAOYSA-N cyclopenta-1,3-diene cyclopenta-2,4-dien-1-yl(diphenyl)phosphane iron(2+) Chemical compound [Fe++].c1cc[cH-]c1.c1cc[c-](c1)P(c1ccccc1)c1ccccc1 GCUVBACNBHGZRS-UHFFFAOYSA-N 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940111685 dibasic potassium phosphate Drugs 0.000 description 1
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- LHWWETDBWVTKJO-UHFFFAOYSA-N et3n triethylamine Chemical compound CCN(CC)CC.CCN(CC)CC LHWWETDBWVTKJO-UHFFFAOYSA-N 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229940124670 gardiquimod Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 102000045715 human TLR7 Human genes 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 208000011379 keloid formation Diseases 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- 208000021601 lentivirus infection Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- RMIODHQZRUFFFF-UHFFFAOYSA-N methoxyacetic acid Chemical compound COCC(O)=O RMIODHQZRUFFFF-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- KDWFDOFTPHDNJL-TUBOTVQJSA-N odn-2006 Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=S)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=S)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(S)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)[C@@H](O)C1 KDWFDOFTPHDNJL-TUBOTVQJSA-N 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940046781 other immunosuppressants in atc Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 102000007863 pattern recognition receptors Human genes 0.000 description 1
- 108010089193 pattern recognition receptors Proteins 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- XNQULTQRGBXLIA-UHFFFAOYSA-O phosphonic anhydride Chemical compound O[P+](O)=O XNQULTQRGBXLIA-UHFFFAOYSA-O 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940072288 prograf Drugs 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 description 1
- 229940099538 rapamune Drugs 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
- 229950005741 rolipram Drugs 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- XFHDOSGLKQJYLP-UHFFFAOYSA-N tert-butyl 2,6-dimethylpiperidine-1-carboxylate Chemical compound CC1CCCC(C)N1C(=O)OC(C)(C)C XFHDOSGLKQJYLP-UHFFFAOYSA-N 0.000 description 1
- ZJQQGLKPJWUKNL-UHFFFAOYSA-N tert-butyl 8-azabicyclo[3.2.1]oct-3-ene-8-carboxylate Chemical compound C1C=CC2CCC1N2C(=O)OC(C)(C)C ZJQQGLKPJWUKNL-UHFFFAOYSA-N 0.000 description 1
- GDYVHALUVFLVMF-UHFFFAOYSA-N tert-butyl 8-azabicyclo[3.2.1]octane-8-carboxylate Chemical compound C1CCC2CCC1N2C(=O)OC(C)(C)C GDYVHALUVFLVMF-UHFFFAOYSA-N 0.000 description 1
- RQCNHUCCQJMSRG-UHFFFAOYSA-N tert-butyl piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1 RQCNHUCCQJMSRG-UHFFFAOYSA-N 0.000 description 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762541331P | 2017-08-04 | 2017-08-04 | |
| PCT/US2018/045080 WO2019028301A1 (en) | 2017-08-04 | 2018-08-03 | INDOLE COMPOUNDS SUBSTITUTED WITH [1,2,4] TRIAZOLO [4,3-A] PYRIDINYL |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2921020T3 true ES2921020T3 (es) | 2022-08-16 |
Family
ID=63364163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18759464T Active ES2921020T3 (es) | 2017-08-04 | 2018-08-03 | Compuestos de indol sustituidos con [1,2,4]triazolo[4,3-a]piridinilo |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11130756B2 (enExample) |
| EP (1) | EP3661934B1 (enExample) |
| JP (1) | JP7266576B2 (enExample) |
| KR (1) | KR102688509B1 (enExample) |
| CN (1) | CN110997670B (enExample) |
| ES (1) | ES2921020T3 (enExample) |
| WO (1) | WO2019028301A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10071079B2 (en) | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
| JP7266576B2 (ja) | 2017-08-04 | 2023-04-28 | ブリストル－マイヤーズ スクイブ カンパニー | ［１，２，４］トリアゾロ［４，３－ａ］ピリジニル置換のインドール化合物 |
| WO2019126113A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Substituted indole compounds useful as tlr inhibitors |
| EP3752505B1 (en) | 2018-02-12 | 2023-01-11 | F. Hoffmann-La Roche AG | Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection |
| SG11202011137SA (en) | 2018-06-05 | 2020-12-30 | Hoffmann La Roche | Tetrahydro-1 h-pyrazino[2,1 -ajisoindolylquinoline compounds for the treatment of autoimmune disease |
| JP7434186B2 (ja) | 2018-06-12 | 2024-02-20 | エフ． ホフマン－ラ ロシュ アーゲー | 自己免疫疾患の処置のための新規のヘテロアリールヘテロシクリル化合物 |
| CN112584903B (zh) | 2018-07-23 | 2025-12-23 | 豪夫迈·罗氏有限公司 | 用于自身免疫性疾病治疗的哌嗪化合物 |
| CN112638908A (zh) | 2018-09-04 | 2021-04-09 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的苯并噻唑类化合物 |
| CN112654618A (zh) | 2018-09-06 | 2021-04-13 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的新型环脒化合物 |
| WO2020048596A1 (en) | 2018-09-06 | 2020-03-12 | F. Hoffmann-La Roche Ag | Novel pyrazolopyridine compounds for the treatment of autoimmune disease |
| EP4051387B1 (en) | 2019-10-31 | 2025-02-19 | F. Hoffmann-La Roche AG | Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease |
| WO2021099284A1 (en) | 2019-11-19 | 2021-05-27 | F. Hoffmann-La Roche Ag | Hydro-1h-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease |
| US12421252B2 (en) | 2019-11-20 | 2025-09-23 | Hoffmann-La Roche Inc. | Spiro (isobenzofuranazetidine) compounds for the treatment of autoimmune disease |
| CA3189873A1 (en) | 2020-08-19 | 2022-02-24 | David S. Yoon | 1h-benzo[d]imidazole derivatives as tlr9 inhibitors for the treatment of fibrosis |
| KR20230053644A (ko) | 2020-08-19 | 2023-04-21 | 브리스톨-마이어스 스큅 컴퍼니 | 섬유증의 치료를 위한 tlr9 억제제로서의 이미다조[1,2-a]피리딘 및 [1,2,4]트리아졸로[1,5-a]피리딘 유도체 |
| CN116783202A (zh) * | 2021-02-09 | 2023-09-19 | 吉利德科学公司 | 噻吩并吡咯化合物 |
| TWI861488B (zh) | 2021-04-16 | 2024-11-11 | 美商基利科學股份有限公司 | 噻吩并吡咯化合物 |
| AU2022341114A1 (en) | 2021-09-10 | 2024-02-29 | Gilead Sciences, Inc. | Thienopyrrole compounds |
| CN114591339B (zh) * | 2022-05-10 | 2022-08-02 | 上海维申医药有限公司 | 一类Toll样受体抑制剂及其制备和应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ20012006A3 (cs) | 1998-12-18 | 2002-03-13 | Axys Pharmaceuticals, Inc. | Sloučenina a farmaceutický prostředek |
| EP1635846A4 (en) | 2003-06-20 | 2009-01-28 | Coley Pharm Gmbh | SMALL MOLECULAR TLR (TOLL-LIKE RECEPTOR) ANTAGONISTS |
| US20060235037A1 (en) | 2005-04-15 | 2006-10-19 | Purandare Ashok V | Heterocyclic inhibitors of protein arginine methyl transferases |
| US20090099179A1 (en) | 2006-04-04 | 2009-04-16 | Myriad Genetics, Incorporated | Compounds for diseases and disorders |
| DE102006033109A1 (de) | 2006-07-18 | 2008-01-31 | Grünenthal GmbH | Substituierte Heteroaryl-Derivate |
| US8027888B2 (en) | 2006-08-31 | 2011-09-27 | Experian Interactive Innovation Center, Llc | Online credit card prescreen systems and methods |
| US7977352B2 (en) | 2006-12-01 | 2011-07-12 | Galapagos Nv | Triazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases |
| WO2008152471A1 (en) | 2007-06-12 | 2008-12-18 | Coley Pharmaceutical Group, Inc. | Quinazoline derivative useful as toll-like receptor antagonist |
| WO2009030996A1 (en) | 2007-09-05 | 2009-03-12 | Coley Pharmaceutical Group, Inc. | Triazole compounds as toll-like receptor (tlr) agonists |
| CN101952286A (zh) * | 2007-12-21 | 2011-01-19 | 阿斯利康(瑞典)有限公司 | 用于治疗和雄激素受体有关的病症的双环衍生物 |
| FR2926556B1 (fr) | 2008-01-22 | 2010-02-19 | Sanofi Aventis | Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique |
| WO2010036905A1 (en) | 2008-09-26 | 2010-04-01 | Eisai R & D Management Co., Ltd. | Benzoxazole compounds and methods of use |
| EP2340243B1 (en) | 2008-10-17 | 2014-10-08 | Boehringer Ingelheim International GmbH | Heteroaryl substituted indole compounds useful as mmp-13 inhibitors |
| TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
| TR201809739T4 (tr) | 2009-07-16 | 2018-07-23 | Mallinckrodt Llc | Toll benzeri reseptör 9 antagonistleri olarak (+)-morfinanlar ve bunların terapötik amaçlı kullanımları. |
| WO2012054862A2 (en) | 2010-10-21 | 2012-04-26 | The Brigham And Women's Hospital, Inc. | Agents, compositions, and methods for treating pruritis and related skin conditions |
| EP3207930A1 (en) | 2011-01-12 | 2017-08-23 | VentiRx Pharmaceuticals, Inc. | Substituted benzoazepines as toll-like receptor modulators |
| HRP20170401T1 (hr) | 2011-01-12 | 2017-05-19 | Ventirx Pharmaceuticals, Inc. | SUPSTITUIRANI BENZOAZEPINI KAO MODULATORI TOLL-u SLIČNIH RECEPTORA |
| RU2606114C2 (ru) | 2011-06-01 | 2017-01-10 | Джейнус Байотерапьютикс, Инк. | Новые модуляторы иммунной системы |
| CA2837207A1 (en) | 2011-06-01 | 2012-12-06 | Janus Biotherapeutics, Inc. | Novel immune system modulators |
| EP2718279B1 (en) | 2011-06-09 | 2016-08-10 | Rhizen Pharmaceuticals SA | Novel compounds as modulators of gpr-119 |
| CN103874702B (zh) | 2011-07-15 | 2015-12-09 | 杨森制药公司 | 作为γ分泌酶调节剂的经取代的吲哚衍生物 |
| US9873694B2 (en) | 2011-10-04 | 2018-01-23 | Janus Biotherapeutics, Inc. | Imidazole quinoline-based immune system modulators |
| KR102194585B1 (ko) | 2012-05-18 | 2020-12-23 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 카르복실산 화합물 |
| JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| EP2738172A1 (en) | 2012-11-28 | 2014-06-04 | Almirall, S.A. | New bicyclic compounds as crac channel modulators |
| WO2015057659A1 (en) | 2013-10-14 | 2015-04-23 | Eisai R&D Management Co., Ltd. | Selectively substituted quinoline compounds |
| EP3080124A1 (en) | 2013-12-13 | 2016-10-19 | Takeda Pharmaceutical Company Limited | Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors |
| UY35935A (es) * | 2014-01-03 | 2015-06-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Compuestos de nicotinamida sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4 |
| WO2016029077A1 (en) | 2014-08-22 | 2016-02-25 | Janus Biotherapeutics, Inc. | Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof |
| US9550778B2 (en) | 2014-10-03 | 2017-01-24 | Vanderbilt University | Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5 |
| US10071079B2 (en) | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
| AU2017307208B2 (en) * | 2016-07-30 | 2021-01-21 | Bristol-Myers Squibb Company | Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors |
| EP3510024B1 (en) * | 2016-09-09 | 2021-11-17 | Bristol-Myers Squibb Company | Pyridyl substituted indole compounds |
| CA3035268A1 (en) * | 2016-09-16 | 2018-03-22 | Nordic Nanovector Asa | Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan |
| JP7266576B2 (ja) | 2017-08-04 | 2023-04-28 | ブリストル－マイヤーズ スクイブ カンパニー | ［１，２，４］トリアゾロ［４，３－ａ］ピリジニル置換のインドール化合物 |
-
2018
- 2018-08-03 JP JP2020505852A patent/JP7266576B2/ja active Active
- 2018-08-03 ES ES18759464T patent/ES2921020T3/es active Active
- 2018-08-03 KR KR1020207005977A patent/KR102688509B1/ko active Active
- 2018-08-03 WO PCT/US2018/045080 patent/WO2019028301A1/en not_active Ceased
- 2018-08-03 EP EP18759464.3A patent/EP3661934B1/en active Active
- 2018-08-03 US US16/635,869 patent/US11130756B2/en active Active
- 2018-08-03 CN CN201880050875.9A patent/CN110997670B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020529436A (ja) | 2020-10-08 |
| KR20200036913A (ko) | 2020-04-07 |
| US11130756B2 (en) | 2021-09-28 |
| KR102688509B1 (ko) | 2024-07-24 |
| CN110997670A (zh) | 2020-04-10 |
| WO2019028301A1 (en) | 2019-02-07 |
| EP3661934B1 (en) | 2022-06-01 |
| CN110997670B (zh) | 2022-11-01 |
| JP7266576B2 (ja) | 2023-04-28 |
| EP3661934A1 (en) | 2020-06-10 |
| US20200369661A1 (en) | 2020-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2921020T3 (es) | Compuestos de indol sustituidos con [1,2,4]triazolo[4,3-a]piridinilo | |
| ES2977657T3 (es) | Compuestos de 6-azaindol | |
| ES2922174T3 (es) | Compuestos de indol sustituidos con amida útiles como inhibidores de TLR | |
| ES2927960T3 (es) | Compuestos de indol éter sustituidos | |
| ES2904676T3 (es) | Compuestos de amino indol útiles como inhibidores de TLR | |
| ES2863474T3 (es) | Compuestos de indol sustituidos con dimetoxifenilo como inhibidores de TLR7, TLR8 o TLR9 | |
| ES2932361T3 (es) | Compuestos de indol sustituidos útiles como inhibidores de TLR | |
| ES2960411T3 (es) | Compuestos de 4-azaindol | |
| ES2886964T3 (es) | Compuestos de indol sustituidos con [1,2,4]triazolo[1,5-a]piridinilo | |
| ES2909401T3 (es) | Compuestos de indol sustituidos útiles como inhibidores de TLR7/8/9 | |
| ES2902504T3 (es) | Compuestos de indol sustituidos con piridilo | |
| ES2965164T3 (es) | Compuestos de carbazol sustituidos | |
| US12172995B2 (en) | Substituted indole and indazole compounds | |
| ES2999539T3 (en) | 1h-benzo[d]imidazole derivatives as tlr9 inhibitors for the treatment of fibrosis | |
| ES2987832T3 (es) | Compuestos de benzimidazolona sustituidos | |
| ES2963696T3 (es) | Compuestos diméricos de indol sustituidos | |
| ES2960521T3 (es) | Compuestos de pirazolo[3,4-D]pirrolo[1,2-B]piridazinilo útiles como inhibidores de IRAK4 |